Abbreviations used in this paper: CAS = carotid artery stenting; CEA = carotid endarterectomy; CTA = CT angiography; DSA = digital subtraction angiography; ICA = internal carotid artery; ICAT = intraluminal carotid artery thrombus; IQR = interquartile range; LMWH = low-molecular-weight heparin; MRA = MR angiography; NASCET = North American Symptomatic Carotid Endarterectomy Trial; NIHSS = NIH Stroke Scale; TIA = transient ischemic attack; UFH = unfractionated heparin.
I ntralumInal carotid artery thrombus is an infrequent finding in patients presenting with TIA or ischemic stroke. It can be a focal process limited to the cervical ICA or a more extensive condition that involves both the extracranial and intracranial ICA, 4 and it can be found in the presence or absence of carotid artery stenosis. When identified in patients without underlying carotid stenosis, it is often associated with a hypercoagulable state. 1, 4 When identified in patients with underlying carotid stenosis, its incidence is correlated to the severity of atherosclerotic disease. In the NASCET, the frequency of ICAT was 1.1% in patients with < 70% stenosis, 4.3% in those with ≥ 70% stenosis, and 5.5% in those with > 85% stenosis.
2,18
Once ICAT is identified, its presence merits special consideration given the high risk of recurrent ischemic events. In the NASCET, patients randomized to antiplatelet medical therapy who had demonstrated ICAT on initial angiography had a significantly higher risk of stroke and death at 1 month postrandomization/posttreatment than did medically treated patients without ICAT (11% vs 2%, respectively). 2, 18 Because of this aggressive clinical course, some consider ICAT an urgent or even emergent condition that requires early CEA; 5, 19 however, the risks
Object. The aim of this study was to define the optimal treatment for patients with symptomatic intraluminal carotid artery thrombus (ICAT).
Methods. The authors performed a retrospective chart review of patients who had presented with symptomatic ICAT at their institution between 2001 and 2011.
Results. Twenty-four patients (16 males and 8 females) with ICAT presented with ischemic stroke (18 patients) or transient ischemic attack ([TIA], 6 patients). All were initially treated using anticoagulation with or without antiplatelet drugs. Eight of these patients had no or only mild carotid artery stenosis on initial angiography and were treated with medical management alone. The remaining 16 patients had moderate or severe carotid stenosis on initial angiography; of these, 10 underwent delayed revascularization (8 patients, carotid endarterectomy [CEA]; 2 patients, angioplasty and stenting), 2 refused revascularization, and 4 were treated with medical therapy alone. One patient had multiple TIAs despite medical therapy and eventually underwent CEA; the remaining 23 patients had no TIAs after treatment. No patient suffered ischemic or hemorrhagic stroke while on anticoagulation therapy, either during the perioperative period or in the long-term follow-up; 1 patient died of an unrelated condition. The mean follow-up was 16.4 months.
Conclusions. Results of this study suggest that initial anticoagulation for symptomatic ICAT leads to a low rate of recurrent ischemic events and that carotid revascularization, if indicated, can be safely performed in a delayed manner.
(http://thejns.org/doi/abs /10.3171/2012.9.JNS12406) associated with this strategy have been considerable. 4 In the NASCET, patients with ICAT who underwent CEA had twice the risk of perioperative stroke and death than did patients without ICAT who underwent CEA (12% vs 6%, respectively). 2, 18 Similarly, in a multicenter retrospective review of symptomatic patients undergoing CEA, those with ICAT had a nearly 3-fold higher risk of perioperative stroke than did patients without ICAT (14% vs 5%, respectively).
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Therefore, optimal management of patients with symptomatic ICAT remains poorly defined. Reported treatment options include medical management utilizing anticoagulation with or without antiplatelet drugs, 4 early carotid revascularization with CEA 3,4 or CAS, 11, 12 and initial medical management using anticoagulation with or without antiplatelet drugs followed by delayed revascularization via CEA 4, 6 or CAS. 9 However, results with each of these therapeutic strategies are based on a few small case series, and available evidence does not provide clarity regarding the best practice for this patient population.
At our institution, patients with symptomatic ICAT are treated using initial anticoagulation followed by delayed revascularization via CEA or CAS, if indicated ( Fig. 1) . In this study, we retrospectively evaluated our experience in the management of patients presenting with TIA or acute ischemic stroke due to ICAT and compared our results with the published literature.
Methods
The Human Research Protection Office approved this study.
Patient Identification
In our practice, DSA is performed as part of the routine care of patients presenting with ischemic symptoms and Doppler ultrasound evidence of ≥ 50% stenosis of the ipsilateral carotid artery to determine whether they are candidates for surgical or endovascular revascularization. Patients who are not good candidates for either procedure because of their health or the severity of their stroke do not undergo DSA. A computerized database of adult patients who had undergone DSA at our institution between January 2001 and February 2011 was queried, and patients with a diagnosed ICAT, defined as a filling defect in the arterial lumen that was visible in at least 2 planes, were identified. All DSA studies were performed by 1 of 3 senior interventional neuroradiologists.
Eligibility Criteria
Symptomatic patients (TIA or stroke) with an intraluminal thrombus in the common carotid artery or extracranial ICAs were included in this study. Exclusion criteria were as follows: 1) thrombus confined to intracranial ICA, 2) thrombus associated with trauma and/or dissection, 3) history of CAS ipsilateral to the thrombus (that is, in-stent thrombosis), 4) ischemic stroke with hemorrhagic transformation, and 5) extensive medical comorbidities at the time of presentation that limited life expectancy.
Chart Review
Medical records of identified patients were retrospectively reviewed, and the following data were collected: age, sex, comorbidities (hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, and chronic heart failure), history of stroke or TIA, current medications (especially antiplatelet agents or anticoagulants), smoking history, clinical presentation (TIA or stroke, number of events prior to diagnosis, time from first event to diagnosis, and NIHSS score at presentation), admission laboratory values (including hemoglobin, hematocrit, and platelet count), angiographic findings at presentation (degree of stenosis bilaterally, location of thrombus relative to stenosis if present, and hemodynamic effect of the thrombus), treatment (use of anticoagulant and antiplatelet agents and duration of anticoagulation), and follow-up (clinical and radiographic). Comorbidities and current medications were identified from a self-reported history. The clinical presentation was considered to be TIA if the patient presented with an acute focal neurological deficit(s) lasting ≤ 24 hours and stroke if there was an acute-onset focal neurological deficit(s) lasting > 24 hours. Duration of symptoms was recorded as 1 day if symptoms were present for 24 hours or less. The NIHSS score was retrospectively assessed from examination findings obtained at admission if it was not directly available in the medical records. 15 Outcome was assessed using radiographic and clinical evaluations by a treating neurologist or neurosurgeon at follow-up. Degree of stenosis was classified per the NASCET criteria.
14 For patients who were receiving anticoagulant drugs at the last follow-up, the interval from initiation of treatment to last follow-up was considered to be the duration of anticoagulation.
In our practice, patients with ICAT who have minimal atherosclerotic disease on initial angiography undergo a diagnostic workup for underlying hypercoagulable conditions including factor V Leiden mutation, prothrombin G20210A mutation, protein C deficiency, protein S deficiency, antithrombin deficiency, antiphospholipid antibody syndrome, and hyperhomocysteinemia. In addition, we previously identified coexisting anemia and thrombocytosis as a risk factor for ICAT in patients without significant underlying carotid stenosis.
1 These data were also extracted from the medical records.
Results

Patient Characteristics
Twenty-four patients (16 males and 8 females) with ICAT satisfying the inclusion and exclusion criteria were identified. The median age at presentation was 55 years (IQR 46-68 years). The majority of patients had known risk factors for stroke: hypertension (54%), hyperlipidemia (50%), smoking history (33%), history of stroke or TIA (25%), coronary artery disease (25%), diabetes mellitus (21%), and atrial fibrillation (4.2%). One female patient (12.5%) had a history of oral contraceptive use. At presentation, 7 patients (29%) were on antiplatelet drugs, and 1 patient (4.2%) was on warfarin for atrial fibrillation with a therapeutic international normalized ratio (2.2).
Among the 24 patients, 7 had a hypercoagulable state: 1 with antiphospholipid antibody syndrome, 1 with systemic lupus erythematosus and thrombocytosis, 1 with essential thrombocytosis, and 4 with iron deficiency anemia with thrombocytosis. A diagnostic workup for other hypercoagulable conditions, including factor V Leiden mutation, prothrombin G20210A mutation, protein C deficiency, protein S deficiency, antithrombin deficiency, antiphospholipid antibody syndrome, and hyperhomocysteinemia, was negative in patients with iron deficiency anemia and thrombocytosis. The median age of patients presenting with hypercoagulability was significantly lower than that of patients without a hypercoagulable state (43 vs 59 years, p = 0.006, Mann-Whitney U-test). Patient characteristics are further outlined in Tables 1 and 2 .
Clinical and Radiographic Presentation
Most patients (75%) presented with ischemic stroke; the remainder presented with TIA. Duration of symptoms ranged from < 3 hours to 4.5 months (median 1 day, IQR 1-2 days). However, all patients were acutely symptomatic, with the last symptomatic episode < 1 week from presentation. The median NIHSS score at presentation was 4 (IQR 1-10) in patients with ischemic stroke. There were insufficient data for NIHSS assessment in 2 patients.
Among the 24 patients, 12 had high-grade stenosis, 4 had moderate stenosis, and 8 had no or mild stenosis on initial angiography per the NASCET criteria. 13 One patient who had presented with TIA and had no carotid stenosis on initial angiography did have a history of ipsilateral CEA for severe stenosis 1 year prior to presentation. Decreased distal flow and/or luminal collapse of the distal ICA due to ICAT was noted in 14 of 24 patients.
Among the 7 patients with a hypercoagulable state, 6 had no or minimal stenosis and 1 had severe stenosis on initial angiography. Decreased distal flow and/or luminal collapse of the distal ICA was seen in 3 of these patients.
Initial Treatment
All patients were treated with anticoagulation at presentation. The anticoagulation regimen varied: UFH only (3 patients), LMWH only (2 patients), warfarin only (1 patient), UFH followed by warfarin (10 patients), UFH with LMWH bridge followed by warfarin (4 patients), LMWH followed by warfarin (3 patients), and UFH followed by LMWH (1 patient). None of the patients had anticoagulation-associated complications. Nineteen patients also received concurrent antiplatelet therapy; 17 were treated with aspirin alone, whereas 2 received aspirin and clopidogrel.
Among patients with a hypercoagulable state, 4 received UFH and warfarin; 2, UFH with LMWH bridge followed by warfarin; and 1, LMWH followed by warfarin. Four patients also received antiplatelet agents (aspirin). Treatment details are summarized in Tables 3 and 4 .
Angiographic Follow-Up
Of the 8 patients with no or mild carotid stenosis on initial DSA, 2 had follow-up vascular imaging. One patient underwent follow-up MRA 12 days after the initiation of anticoagulation to evaluate new-onset headache. Imaging studies showed complete resolution of the ICAT and the absence of residual carotid stenosis. The other patient underwent follow-up CTA 7 months after the initiation of anticoagulation given uncertainty regarding the degree of stenosis on initial DSA (49%). Complete resolution of the ICAT and mild residual stenosis was noted. Of the 16 patients with moderate or high-grade stenosis on initial DSA, 11 underwent repeat vascular imaging (all DSA). Complete resolution of the ICAT was observed in 10 of these 11 patients, whereas 1 had substantial but incomplete resolution of the ICAT. Residual moderate to severe stenosis was observed in 10 of these 11 patients, while 1 patient had only minimal residual stenosis. Follow-up data are outlined further in Tables 3 and 4 .
Delayed Revascularization
Among the 8 patients with no or mild carotid stenosis on initial DSA, none were offered delayed revascularization. Among the 16 patients with moderate to high-grade carotid stenosis on initial DSA, 8 underwent delayed CEA, 2 underwent delayed CAS, 2 refused delayed revascularization, 3 were not offered delayed revascularization (2 because of severe comorbidities and 1 because of downgrading carotid stenosis to minimal on repeat DSA), and 1 was lost to follow-up after initiation of anticoagulation. The mean interval from clinical presentation to delayed revascularization was 39.3 days (range 15-91 days).
Clinical Follow-Up
The mean duration of anticoagulation was 30 days (range 7-53 days) in the 10 patients who underwent delayed revascularization and 103 days (range 7-318 days) in the 13 patients who underwent medical therapy alone (duration of anticoagulation was not available in 1 patient, who was lost to follow-up). The mean duration of clinical follow-up for the entire patient cohort was 70 weeks (range 5-368 weeks). No patient in this cohort suffered a recurrent ischemic stroke. One patient (4.2%) with highgrade stenosis on initial DSA experienced TIAs while on anticoagulation. He underwent follow-up DSA studies 28 days after the initiation of anticoagulation, which revealed substantial but incomplete resolution of the ICAT and 90% residual carotid stenosis. He underwent an uncomplicated CEA the next day, and no evidence of ICAT was noted; he experienced no recurrent ischemic events in the long-term follow-up (74.5 weeks). Among patients who underwent delayed revascularization via CEA or CAS, none suffered perioperative ischemic stroke or death. One patient had a post-CEA neck hematoma that required surgical evacuation. No procedural complications were noted in those undergoing CAS.
In the long-term follow-up, 1 patient died due to complications of metastatic breast cancer. This patient had no ischemic complications during the 90.2 weeks of available follow-up. There were no other patient deaths. One patient was lost to follow-up.
Discussion
Symptomatic ICAT is associated with a high risk of recurrent ischemic events and poor patient outcome.
2 Optimal management of this patient population remains controversial, mainly because of the rarity of reported cases. Here, we report excellent results with a strategy of initial anticoagulation followed by delayed revascularization (as indicated). None of the 24 patients in this study (14 treated with anticoagulation alone, and 10 treated with anticoagulation followed by delayed revascularization) suffered new ischemic or hemorrhagic stroke, and none suffered ICAT-related death in the late clinical follow-up (mean follow-up 70 weeks; Tables 1-4) . When comparing our results with those in published reports of strategies of antiplatelet therapy alone (11% risk of stroke and death at 1 month posttreatment) 2, 18 or early CEA (12%-14% risk of stroke and death at 1 month posttreatment), 2, 8, 18 the strategy of initial anticoagulation with or without antiplatelet therapy to permit ICAT resolution followed by delayed revascularization (if needed) appears superior (Table 5) .
Results from smaller case series in which patients with ICAT were treated with anticoagulation alone or in combination with delayed revascularization generally echo our experience (Table 5 ). Buchan et al.
4 treated 6 patients with ICAT by using anticoagulation alone and reported no recurrent ischemic events and no deaths in the late follow-up. They treated 3 additional patients with ICAT by using initial anticoagulation followed by delayed CEA and reported no recurrent ischemic events in the interval between initiation of anticoagulation and surgery. However, 1 of these 3 patients did suffer a fatal post-CEA stroke. Combe et al. 6 treated 5 patients with ICAT and González et al. 9 treated 3 patients with ICAT by using initial anticoagulation followed by delayed CEA and reported no recurrent ischemic events in the interval between initiation of anticoagulation and surgery as well as no incidence of post-CEA stroke or death.
Two alternative approaches to the management of patients with ICAT and suspected underlying stenosis have been reported-early CEA and early CAS (Table 5) . Regarding early CEA, results from the NASCET (12% perioperative stroke or death rate for patients with ICAT vs 6% perioperative stroke or death rate for patients without ICAT) and a large multicenter retrospective review 8 (14% perioperative stroke rate for patients with ICAT vs 5% perioperative stroke rate for patients without ICAT) strongly suggest that this treatment strategy for patients 4 treated 14 patients with ICAT by using early CEA and noted a 29% risk of perioperative stroke or death. In contradistinction, Caplan et al. 5 treated 6 patients by using early CEA and noted a 0% risk of perioperative stroke or death.
Regarding early CAS in patients with ICAT and underlying stenosis, initial results have been more favorable than those reported for early CEA. In the first reported case series, Tsumoto et al.
17 treated 6 patients with ICAT by using early CAS and noted a 17% risk of perioperative stroke or death. However, 2 subsequent series of 9 patients with ICAT 11 and 6 acute stroke patients with ICAT 12 noted a 0% risk of stroke or death following early CAS. Taken together, these 3 small case series 11, 17 and other individual case reports 10, 17 suggest that early CAS for the treatment of patients with symptomatic ICAT may be a reasonable approach, although the number of reported cases remains small. However, it should be noted that the degree of stenosis in many of these patients may be minimal once the thrombus has lysed. Our data suggest that anticoagulation for a week to 10 days followed by reimaging may avoid a revascularization procedure in many patients, with minimal risk of stroke.
In most cases, ICAT occurs in the setting of underlying atherosclerotic disease that predisposes to thromboembolism; 6 however, it has also been reported in the absence of significant atherosclerotic disease. The latter usually occurs in the setting of a hypercoagulable state. 1, 5, 7, 16, 20 In our study, 7 patients had a hypercoagulable condition, the most common of which was thrombocytosis. The formation of ICAT in the setting of essential thrombocytosis or anemia with secondary thrombocytosis is rare, with only a few reported cases. 1, 5, 7, 16, 20 Our results with a strategy of anticoagulation in this subset of patients with ICAT suggest that medical management may be preferred to early CEA or early CAS.
Our study has several limitations. First, it is a retrospective case series with limitations inherent to the study design. Second, follow-up angiography to confirm thrombus resolution was not performed in all patients. Third, the methods and duration of anticoagulation used in our series were varied. Fourth, the concurrent use of antiplatelet therapy during the period of anticoagulation was not uniform. Fifth, the small sample size of our series could have underestimated the true incidence of stroke or death in patients treated with our strategy of anticoagulation alone or anticoagulation followed by delayed revascularization. Given the rarity of this condition, however, such limitations would be difficult to avoid.
Conclusions
In summary, this case series is the largest to date demonstrating that patients with symptomatic ICAT can be managed safely and effectively via a strategy of initial 
